Get the Stockscreener App
2.11
7.05%
-0.16
Omniab Inc stock is traded at $2.11, with a volume of 468.91K.
It is down -7.05% in the last 24 hours and down -3.21% over the past month.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.
See More
Previous Close:
$2.27
Open:
$2.31
24h Volume:
468.91K
Relative Volume:
0.74
Market Cap:
$305.89M
Revenue:
$28.94M
Net Income/Loss:
$-54.29M
P/E Ratio:
-4.5406
EPS:
-0.4647
Net Cash Flow:
$-26.02M
1W Performance:
-7.46%
1M Performance:
-3.21%
6M Performance:
+3.94%
1Y Performance:
+18.54%
1-Day Range:
$2.065
$2.365
1-Week Range:
$2.065
$2.505
52-Week Range:
$1.30
$2.79
Omniab Inc Stock (OABI) Company Profile
Name
Omniab Inc
Sector
Industry
Phone
510-250-7800
Address
5980 HORTON STREET, EMERYVILLE
Compare OABI vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OABI
Omniab Inc
|
2.11 | 305.89M | 28.94M | -54.29M | -26.02M | -0.4647 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Omniab Inc Stock (OABI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-29-23 | Initiated | RBC Capital Mkts | Outperform |
| Apr-21-23 | Initiated | The Benchmark Company | Buy |
| Apr-13-23 | Initiated | Craig Hallum | Buy |
| Feb-22-23 | Initiated | Cowen | Outperform |
| Feb-13-23 | Initiated | H.C. Wainwright | Buy |
| Dec-20-22 | Initiated | Truist | Buy |
| Dec-16-22 | Initiated | Credit Suisse | Outperform |
| Nov-29-22 | Initiated | SVB Leerink | Outperform |
| Nov-28-22 | Initiated | Stifel | Buy |
View All
Omniab Inc Stock (OABI) Latest News
OABI Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive SentimentAnalyst Consensus Shift - newsline.com
OmniAb, Inc. Hits New 52-Week High of $2.79 Amidst Market Challenges - Markets Mojo
Companies Like OmniAb (NASDAQ:OABI) Are In A Position To Invest In Growth - Yahoo Finance
OmniAb Inc. (OABI) Gains 3.26% as Stock Approaches Key Resistance LevelAnalyst Upgrade Stocks - newsline.com
OABI Stock Price, Quote & Chart | OMNIAB INC (NASDAQ:OABI) - ChartMill
OmniAb Inc. (OABI) Edges Lower as Stock Nears Key Support ZoneFibonacci Retracement - newsline.com
OmniAb (OABI) Hovers Near Key Support After Slight DeclineRunaway Gap - The Legal Advocate
OABI Q1 2026 Earnings: EPS Beat Masks Ongoing R&D InvestmentsUpward Estimate Revision - newsline.com
OABI Q1 2026 Earnings: Wider-than-Expected Loss Narrows as EPS Surprises PositivelyEarnings Yield Spread - newsline.com
OmniAb, Inc. Hits New 52-Week High at USD 2.73 - Markets Mojo
OmniAb Stock Is Back Near Its High — Why OABI’s Next Few Days Matter - Bez Kabli
OmniAb Inc. (OABI) Gains 3.92% as Stock Approaches Key Resistance at $2.78Narrow Range Breakout - newsline.com
OmniAb Inc. (OABI) Shares Edge Higher as Key Support HoldsOn Balance Volume - thelegaladvocate.com
OmniAb Inc. (OABI) Rallies 3.9% as Stock Tests Key Resistance LevelsLinear Regression - The Legal Advocate
Is OmniAb Positioned To Be A Long-Term Biotech Winner? - RTTNews
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Sahm
OmniAb, Inc. Common Stock OABI ) Stock Price Today & Analysis - Gotrade
OmniAb unveils OmniUltra in vivo platform at TIDES USA event - Traders Union
OmniAb, Inc. (OABI) reports Q1 loss, tops revenue estimates - MSN
We're Hopeful That OmniAb (NASDAQ:OABI) Will Use Its Cash Wisely - Moomoo
TradingKey - TradingKey
OmniAb forecasts $28M-$33M 2026 revenue as partner milestones lift outlook - MSN
OmniAb, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:OABI) 2026-05-11 - Seeking Alpha
Number of shareholders of OmniAb, Inc. – NASDAQ:OABIW - TradingView
OmniAb (NASDAQ:OABI) Issues Earnings Results - MarketBeat
OmniAb Reports Strong Revenue Growth Driven by Clinical Partner Progress - HarianBasis.co
OmniAb, Inc. (NASDAQ:OABI) Q1 2026 Earnings Call Transcript - Insider Monkey
OmniAb (OABI) FY 2025 Loss Of US$64.8m Keeps Profitability Narrative Under Pressure - Sahm
OmniAb Earnings Call Highlights Surge In Milestones - TipRanks
OmniAb’s Q1 2026 Revenue Rises to $25.3 Million, Net Loss Decreases - geneonline.com
OmniAb unveils in vivo platform for human antibody and peptide discovery at 2026 PEGS Summit - Traders Union
OmniAb (OABI) Q1 2026 Earnings Transcript - AOL.com
Craig-Hallum Maintains OmniAb(OABI.US) With Buy Rating, Announces Target Price $7 - Moomoo
OmniAb, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
OmniAb Q1 2026 slides: revenue surges 243%, guidance raised By Investing.com - Investing.com Australia
OmniAb Q1 Earnings Call Highlights - MarketBeat
TD Cowen Maintains OmniAb(OABI.US) With Buy Rating, Maintains Target Price $3 - Moomoo
H.C. Wainwright Maintains OmniAb(OABI.US) With Buy Rating, Maintains Target Price $11 - Moomoo
The organic vs inorganic growth story at OmniAb (OABI) | Q1 2026: EPS Beats ForecastsAI Stock Signals - newser.com
OmniAb Reports First Quarter 2026 Financial Results and Business Highlights - BioSpace
OmniAb, Inc. (OABI) Reports Q1 Loss, Tops Revenue Estimates - Yahoo! Finance Canada
Earnings call transcript: OmniAb Q1 2026 sees revenue surge, stock climbs - Investing.com
Omniab Inc Stock (OABI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):